FDA clears PK Med to streamline gout injectable to Phase II

26 Feb 2024
www.pharmaceutical-technology.com
Phase 2Phase 3Drug ApprovalIND
FDA clears PK Med to streamline gout injectable to Phase II
Preview
Source: Pharmaceutical Technology
The number of diagnosed prevalent cases of gout will be 25,961,819 in 2032, according to GlobalData. Credit: ThamKC via Shutterstock.
France-based biotechnology company PK Med has received clearance from the US Food and Drug Administration (FDA) to advance its injectable gout treatment PKM-01 into Phase II clinical trials, without undergoing Phase I studies.
The Phase II trial will evaluate three doses of PKM-01, a combined treatment of controlled-release colchicine with ropivacaine, an anaesthetic. The prospective, randomised study aims to select the optimal dose of the treatment to further advance it into Phase III trials.
PKM-01 is an intra-articular injectable treatment candidate for gout flares. Unlike current treatment regimens, ropivacaine’s anaesthetic effect is expected to alleviate pain within minutes of injection. Oral colchicine, a standard anti-inflammatory treatment for gout, can only be used in low doses due to toxicity and systemic exposure. PKM-01’s localised colchicine delivery aims to offer potent, lasting pain and inflammation relief without the systemic risks associated with standard-of-care treatments.
Gout is a type of arthritis that occurs when there is a buildup of uric acid in the body, leading to the formation of urate crystals in the joints. This can cause sudden and severe pain, swelling, and inflammation – typically in the big toe but can affect other joints as well.
According to a report on GlobalData’s Pharmaceutical Intelligence Center, the number of diagnosed prevalent cases of gout is predicted to be 25,961,819 in 2032. The gout market is forecast to be worth $10.77bn in 2032, an increase from $4.63bn in 2022.
See Also:Streamlining supply chain operations in focus at Clinical Trial Supply Europe 2024
FDA clears PK Med to streamline gout injectable to Phase II
Preview
Source: Pharmaceutical Technology
FDA approves Alvotech-Teva’s SIMLANDI jab for multiple conditions
FDA clears PK Med to streamline gout injectable to Phase II
Preview
Source: Pharmaceutical Technology
GlobalData is the parent company of Pharmaceutical Technology.
There are several therapies in the late-stage pipeline for gout, most of which are urate-lowering therapies or anti-inflammatory therapies, one of which being Dapansutrile, an inflammasome inhibitor forecast to launch in 2026 – potentially offering an improved safety profile for long-term use compared to the current treatment regimen of nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine, as per a GlobalData analyst.
In the 26 February announcement accompanying the FDA clearance, PK Med CEO Gauthier Pouliquen said: “This FDA feedback is excellent news for clinicians and patients suffering from gout flares. It should significantly accelerate the time-to-market for PKM-01. PK MED is now entering the fund-raising phase to finance PKM-01 Phase II clinical trials. With robust patent protection and a clear path to deliver Phase II results, PKM-01 represents an attractive and low-risk opportunity for investors and partners.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.